Serina Fischer appointed GM India at Takeda Pharmaceuticals

Serina has over 17 years of experience in the biopharmaceutical industry

Granules strengthens ADHD portfolio with FDA approval for Lisdexamfetamine Dimesylate capsules

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older

Granules India FDA approval for ADHD treatment

Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules

The product will be manufactured at Lupin’s Somerset facility in the US

Lupin appoints Claus Jepsen as President, Global Specialty

Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan

This license will enable Abbott to enhance access to this novel therapy to more patients across India

Alembic announces USFDA final approval for Icatibant injection

This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals

Torrent inks licensing agreement with Takeda to commercialize its novel gastrointestinal drug in India

Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders

Lupin receives USFDA’s approval for Febuxostat Tablets

Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)

Alembic received 6 USFDA approvals during Q2FY24

The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets